Reduced IL-2 expression in NOD mice leads to a temporal increase in CD62Llo FoxP3+ CD4+ T cells with limited suppressor activity.
about
Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunityCellular mechanisms of restored β-cell tolerance mediated by protective alleles of Idd3 and Idd5Premature CD4+ T cell aging and its contribution to lymphopenia-induced proliferation of memory cells in autoimmune-prone non-obese diabetic miceIncreased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production.Genetic interactions among Idd3, Idd5.1, Idd5.2, and Idd5.3 protective loci in the nonobese diabetic mouse model of type 1 diabetes.IL-Y, a synthetic member of the IL-12 cytokine family, suppresses the development of type 1 diabetes in NOD miceβ-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice.Chronic follicular bronchiolitis requires antigen-specific regulatory T cell control to prevent fatal disease progression.Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvementReestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.Expression of IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabetes through activation of FoxP3-positive regulatory T cells.β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice.Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs.Reduced interleukin-2 responsiveness impairs the ability of Treg cells to compete for IL-2 in nonobese diabetic mice.IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint.CD40 engagement of CD4+ CD40+ T cells in a neo-self antigen disease model ablates CTLA-4 expression and indirectly impacts tolerance
P2860
Q27008200-7DF20E1D-7838-4537-AF08-A9E47501665CQ28253641-037F812F-E45F-4F4E-ABF6-15B31FA47973Q35107187-CDB3A63D-CC0E-426C-AEFE-57244113CEE9Q35845445-BD94A26F-8099-4FE2-9E57-13A2D74C7BB9Q36718178-5F56793A-597A-4B52-8F03-DB65CA5427D7Q36774544-708B080A-0685-47AA-B7E3-6BE87DC29C03Q37251067-38F526B8-0E24-435B-A85D-D84EECC9A593Q37486824-BD891FDF-7D9F-4601-895D-BFCFE2B73E4BQ37522254-7C48862A-2779-4AB3-9CDC-42B84DF37B9CQ38384138-78150C05-577A-4921-8C51-2AFC47956ACEQ38449217-99FEE43B-6942-4391-B3EC-656A65E2EA0EQ38730525-EF755C5F-7EBF-4496-AC18-129A337C081CQ40895314-1451D034-5D6F-4137-9BA0-018D756B318CQ53210404-A2EC3912-D88C-4433-BBCA-6DE23D1D8DB8Q53467545-4370D780-252F-4948-BE47-C9B2A18F2A27Q56898286-F8C4E73C-8B97-4A08-AB09-C5B15749A089
P2860
Reduced IL-2 expression in NOD mice leads to a temporal increase in CD62Llo FoxP3+ CD4+ T cells with limited suppressor activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reduced IL-2 expression in NOD ...... h limited suppressor activity.
@en
Reduced IL-2 expression in NOD ...... h limited suppressor activity.
@nl
type
label
Reduced IL-2 expression in NOD ...... h limited suppressor activity.
@en
Reduced IL-2 expression in NOD ...... h limited suppressor activity.
@nl
prefLabel
Reduced IL-2 expression in NOD ...... h limited suppressor activity.
@en
Reduced IL-2 expression in NOD ...... h limited suppressor activity.
@nl
P2093
P2860
P356
P1476
Reduced IL-2 expression in NOD ...... h limited suppressor activity.
@en
P2093
Alaina Garland
Chengwen Li
Kevin S Goudy
Mark C Johnson
Richard J Samulski
Roland Tisch
P2860
P304
P356
10.1002/EJI.201040890
P407
P577
2011-04-20T00:00:00Z